Focus Issue: Mechanistic Insights and Drug TherapyOriginal ResearchEfficacy of Tafamidis in Patients With Hereditary and Wild-Type Transthyretin Amyloid Cardiomyopathy: Further Analyses From ATTR-ACT
Original Research
Under a Creative Commons license
open access
Central Illustration
Key Words
clinical trial
hereditary
tafamidis
transthyretin amyloid cardiomyopathy
wild-type
Abbreviations and Acronyms
6MWT
6-min walk test
ATTR-CM
transthyretin amyloid cardiomyopathy
ATTRv
variant transthyretin amyloidosis
ATTRwt
wild-type transthyretin amyloidosis
CI
confidence interval
KCCQ-OS
Kansas City Cardiomyopathy Questionnaire Overall Summary
NT-proBNP
N-terminal pro–B-type natriuretic peptide
NYHA
New York Heart Association
TTR
transthyretin
Cited by (0)
The authors attest they are in compliance with human studies committees and animal welfare regulations of the authors’ institutions and Food and Drug Administration guidelines, including patient consent where appropriate. For more information, visit the Author Center.
© 2021 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation.